Johnson & Johnson

News

Dizal breaks new ground for EGFR drugs in lung cancer

Dizal's Zegfrovy has taken the oral EGFR inhibitor class into new territory, with a phase 3 win as a frontline treatment for a form of lung cancer.

News

J&J gets FDA okay for psoriasis drug icotrokinra

Johnson & Johnson's much-anticipated oral IL-23 drug, icotrokinra, has claimed FDA approval as Icotyde for first-line treatment of plaque psoriasis.

News

Yellow balloons with smiling faces drawn on them in black ink

J&J says Inlexzo follow-up 'promising' in bladder cancer

Johnson & Johnson says localised delivery of its FGFR inhibitor erdafitinib could provide the first targeted treatment for early‑stage bladder cancer.

News

Incyte breaks new ground in anal cancer with EU approval

Incyte claims EU approval for Zynyz as the first systemic therapy for anal cancer, as J&J gets the nod for wider use of Akeega in prostate cancer.

News

J&J's Tecvayli claims third national priority FDA approval

J&J claims the FDA's third national priority voucher approval, advancing a Tecvayli-based regimen for multiple myeloma into the second-line setting.

News

CMS's Medicare price negotiations start round three

The US federal government has named the next 15 big-selling medicines that will be subject to Medicare pricing negotiations.

Dizal breaks new ground for EGFR drugs in lung cancer

J&J gets FDA okay for psoriasis drug icotrokinra

J&J says Inlexzo follow-up 'promising' in bladder cancer

Incyte breaks new ground in anal cancer with EU approval

J&J's Tecvayli claims third national priority FDA approval

CMS's Medicare price negotiations start round three

LSX2026: On promise and patience, with Hans Schambye

Using AI-driven synthetic personas to take your insights fur...

Johnson & Johnson

Editor's Picks